Scarica l'app Stockscreener
11.19
0.58%
0.065
Artiva Biotherapeutics Inc Borsa (ARTV) Ultime notizie
Artiva (ARTV) Earnings Update: The Bottom-Line Figure Outpaces Its Comparison on the Day; Post-Report: The Market Price Moves 0.17% Higher for the Current SessionEPS Revision Trend - vinanet.vn
Artiva Biotherapeutics CMO sells $5,148 in stock By Investing.com - Investing.com South Africa
Artiva Biotherapeutics CMO sells $5,148 in stock - Investing.com
Artiva Biotherapeutics: Targeting A Potentially Lucrative Niche (NASDAQ:ARTV) - Seeking Alpha
ARTV Q2 2026 Earnings: Narrower Loss of $0.63 per Share, But Stock Slips 0.35%Debt Analysis Report - vinanet.vn
What is HC Wainwright's Forecast for ARTV Q3 Earnings? - MarketBeat
Artiva Biotherapeutics (ARTV) Slips to $11.22 as Stock Holds Above Key SupportSmart Beta Flow - dars.gov.et
ARTV Q2 2026 Earnings: Narrower-Than-Expected Loss Signals Expense Discipline for Clinical-Stage DeveloperNew Analyst Coverage - vinanet.vn
Wall Street Zen Upgrades Artiva Biotherapeutics (NASDAQ:ARTV) to Hold - MarketBeat
TD Cowen Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating, Announces Target Price $11.58 - Moomoo
H.C. Wainwright Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating, Maintains Target Price $35 - Moomoo
ARTIVA BIOTHERAPEUTICS INC: QTRLY EPS $-0.63 - webull.com
Artiva Therapeutics: Buy Rating Reiterated on Strong AlloNK RA Profile and Upcoming Phase III, Price Target Maintained at $41 - TipRanks
Artiva Therapeutics: Buy Rating Reiterated on Promising RA Data, Clear Phase 3 Path and Maintained $35 Price Target - TipRanks
Certain Restricted Stock Units of Artiva Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-AUG-2026. - marketscreener.com
Certain Stock Options of Artiva Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-AUG-2026. - marketscreener.com
Artiva Biotherapeutics (NASDAQ:ARTV) Announces Quarterly Earnings Results - MarketBeat
Artiva Biotherapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights - The Manila Times
Artiva Biotherapeutics reports Q2 2026 net loss $25.0M, cash $349.4M to fund operations into 2029 - TradingView
FDA RMAT designation for AlloNK plus rituximab boosts Artiva Biotherapeutics, Inc. clinical progress - Traders Union
Artiva Biotherapeutics stock surges on positive trial data By Investing.com - Investing.com Nigeria
Form DEF 14A Artiva Biotherapeutics For: 3 August By Investing.com - Investing.com Nigeria
Form 4 Artiva Biotherapeutics Inc For: 1 August By Investing.com - Investing.com Canada
Ra capital management, 10% owner, acquires $455,725 Artiva stock By Investing.com - Investing.com Canada
Artiva Biotherapeutics (NASDAQ:ARTV) Director Purchases $247,693.92 in Stock - MarketBeat
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Form 4 Artiva Biotherapeutics Inc For: 28 July By Investing.com - Investing.com Nigeria
RA Capital Management Boosts Artiva Biotherapeutics Stake with $412,000 Stock Acquisition - Kalkine Media
Artiva Biotherapeutics Inc (ARTV) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Artiva Biotherapeutics Inc (ARTV) Cash Flow - TradingKey
ARTV|Artiva Biotherapeutics Inc|Price:10.340|Chg%:+0.310 - TradingKey
Artiva Biotherapeutics Inc (ARTV) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Artiva Biotherapeutics Inc (ARTV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TradingKey - TradingKey
ARTV News | ARTIVA BIOTHERAPEUTICS INC (NASDAQ:ARTV) - ChartMill
Insider Stock Purchases: July 24, 2026 | ARTV Stock News - Quiver Quantitative
Thursday’s insider buys and sells: Artiva, StoneX and CoreWeave By Investing.com - Investing.com South Africa
Ra capital management, director, buys $58,306 of Artiva stock - Investing.com UK
Ra capital management, director, buys $58,306 of Artiva stock By Investing.com - Investing.com India
RA Capital Management acquires USD 2.62 million of Artiva Biotherapeutics common shares - Bitget
Form 4 Artiva Biotherapeutics Inc For: 23 July By Investing.com - Investing.com Nigeria
Form 13D/A ARTIVA BIOTHERAPEUTICS For: 23 July By Investing.com - Investing.com Nigeria
Ra Capital Management buys $2.58m in Artiva Biotherapeutics stock By Investing.com - Investing.com Australia
Ra Capital Management buys $2.58m in Artiva Biotherapeutics stock - Investing.com
ARTV Options Volatility — NASDAQ:ARTV - TradingView
ARTV Options Chain — NASDAQ:ARTV - TradingView
Artiva Biotherapeutics Sets Deadline for 2026 Meeting - TipRanks
Artiva sets 2026 annual meeting for Sept. 8; stockholder notice deadline Aug. 1 - TradingView
Artiva Biotherapeutics (Nasdaq: ARTV) details 2026 meeting deadlines - Stock Titan
Major Insider Move Signals Growing Confidence in Artiva Biotherapeutics - TipRanks
Artiva Biotherapeutics (ARTV) Slumps 6.25%: Approaching Key Support at $8.69Regression Channel - vinanet.vn
New Form 4 - Moomoo
Artiva Biotherapeutics Inc. (ARTV) Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineProfit Growth Outlook - vinanet.vn
Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):